Overview

Memantine Augmentation of Antidepressants

Status:
Completed

Trial end date:
2011-12-01

Target enrollment:

Participant gender:

Summary

This study is evaluating the efficacy and safety of the drug memantine (trade name NAMENDA) as an augmentation agent for the treatment of depression in people who are not fully responding to antidepressant medications.

Phase:

Phase 4

Details

Lead Sponsor:

University of Massachusetts, Worcester

Collaborator:

Forest Laboratories

Treatments:

Antidepressive Agents
Memantine